Kaplan-Meier plots for progression free survival for patients with KRAS wild type (19 statin-users and 145 nonusers) and KRAS mutant (16 statin-users and 83 nonusers) tumors treated with capecitabine, oxaliplatin, bevacizumab and cetuximab.

Authors
Publication date
Publisher
Doi

    Abstract

    <p>Kaplan-Meier plots for progression free survival for patients with KRAS wild type (19 statin-users and 145 nonusers) and KRAS mutant (16 statin-users and 83 nonusers) tumors treated with capecitabine, oxaliplatin, bevacizumab and cetuximab.</p

      Similar works

      Full text

      thumbnail-image

      Available Versions

      FigShare

      redirect
      oaioai:figshare.com:article/12317...
      Last time updated on 12/02/2018